19815 Bay Branch Rd
Andalusia, Alabama 36420
(334) 222-2523
HELPLINE: 1-877-530-0002



SCAMHC is an approved Mental Health site for the National Health Service Corps Loan Repayment program.  Find out the program details and see if you qualify by visiting: http://nhsc.hrsa.gov/

SCAMHC is an Equal Opportunity Provider and Employer and maintains a Drug-Free Workplace





powered by centersite dot net
Women's Health
Basic InformationLatest News
Exercise Might Make Breast Milk's Goodness Even BetterPreterm Birth Ups Mom's Long-Term Heart Disease Risk: StudyAffection, at Least for Women, May Be Rooted in GenesHormones May Explain Greater Prevalence of Alzheimer's in WomenCoronavirus Delivering a Big Economic Blow to WomenAHA News: Persistent Depression Might Increase Heart Disease Risk for Women With HIVStatins Tied to Significantly Lower Death Rate From Ovarian CancerPandemic Affecting Mental Health of Pregnant Women, New MomsClimate Change, Smog Could Mean More Preemie Babies: StudyFemale Athletes Shortchange Themselves on NutritionWomen Still Left Out of Much Medical ResearchAHA News: Pregnant Women With Heart Defects Don't Always Get This Recommended TestNot a Myth -- Contraceptives Can Cause Weight GainMeds Like Valium, Xanax Linked to Higher Risk of Ectopic PregnancyAt-Home Gene Test for Breast, Ovarian Cancers Looks EffectivePlacenta's Hidden Mysteries Revealed in MRI StudyLost Pregnancies, Diabetes May Be LinkedWomen Less Likely to Get Standard Heart MedicationsGood News for Menopausal Women Who Take HopsBlack and White Women Share the Same Genetic Risk for Breast Cancer'Good Bacteria' Might Help Fight a Common Gynecologic InfectionMore Evidence Sugary Drinks Harm Women's HeartsAHA News: Prenatal Supplement May Increase Blood Pressure at High DosesMammograms Do Save Women's Lives, Study FindsBreastfeeding May Help Guard Against DiabetesAHA News: How Pregnant Woman's High Blood Pressure Can Change Shape of Baby's HeartMenopause May Someday Disappear as Women Postpone Pregnancy: StudyRural Women at Higher Risk of Early Death From Heart DiseaseEven During Pandemic, Childbirth Safest in Hospital, Doctors' Group SaysDo C-Section Babies Become Heavier Adults?High-Fiber Diets May Lower Odds for Breast CancerWomen in Their 50s Can Lower Their Stroke Risk – Here's HowMental Health Problems After First Baby Reduce Likelihood of More Children: StudyWhen Arteries Narrow, Chest Pain Can Come Earlier for Women Than MenRacial, Ethnic Gaps in Insurance Put Moms, Babies at Risk: StudyStatins Might Reduce Harms From Breast Cancer ChemoExpectant Moms: Take Care and Don't Panic About CoronavirusGene Tests May Guard Older Breast Cancer Patients Against Other TumorsAHA News: Changing the Way We View Women's Heart Attack SymptomsMaria Shriver Sounds the Alarm on Women and Alzheimer'sAHA News: Estrogen Therapy in Early Menopause May Help Keep Arteries ClearDon't Wait, for Your Baby's Sake: Quit Smoking Before You're PregnantFemale Firefighters Face Higher Exposure to CarcinogensNew Moms Need to Watch Out for High Blood PressureBad Sleep, Bad Diet = Bad Heart?A Woman's Guide to Skin Care During and After MenopauseAHA News: What Women Need to Know About Breast Cancer and Heart DiseaseIs High Blood Pressure in First Pregnancy a Harbinger of Heart Trouble?AHA News: Domestic Abuse May Do Long-Term Damage to Women's Health'Couch Potato' Lifestyle Poses Danger to Women's Hearts
Questions and AnswersVideosLinksBook ReviewsSelf-Help Groups
Related Topics

Wellness and Personal Development
Mental Disorders

Statins Tied to Significantly Lower Death Rate From Ovarian Cancer

HealthDay News
by -- Steven Reinberg
Updated: Jun 22nd 2020

new article illustration

MONDAY, June 22, 2020 (HealthDay News) -- Statin drugs, used for decades to treat high cholesterol, may also reduce deaths for women with ovarian cancer, a new study suggests.

"These drugs are appealing as they are widely used, inexpensive, and well-tolerated in most patients. The associated reduction in ovarian cancer mortality is promising," said lead researcher Dr. Kala Visvanathan, a professor of epidemiology and oncology at Johns Hopkins Bloomberg School of Public Health in Baltimore.

She pointed out that drugs to combat ovarian cancer are sorely needed, given its reputation as a "silent killer."

That's because "there are no proven screening strategies" to catch ovarian tumors early, Visvanathan said, "so the disease is typically diagnosed at an advanced stage, when surgery is often not an option."

In the new study, her team collected data on more than 10,000 women with ovarian cancer who were part of a Finnish national cancer registry. Among these women, more than 2,600 had used a statin, and 80% used so-called lipophilic statins, such as simvastatin and lovastatin -- a form of the drug that dissolves within fats.

Using of any type of statin was linked with a 40% lower death rate, compared with women not using statins, Visvanathan and colleagues found. The use of lipophilic statins, specifically, were tied to a 43% risk of dying from ovarian cancer, the researchers found.

The most significant reductions in death after using statins were among women with specific subtypes of ovarian cancer -- high-grade serous carcinoma (a 40% reduction) and endometrioid ovarian cancer (50% reduction).

Even women who started using lipophilic statins after being diagnosed with ovarian cancer had a lower odds of dying, the researchers noted.

The results of the study were scheduled to be presented June 22 at an online meeting of the American Association for Cancer Research.

"Our results provide further evidence in support of the clinical evaluation of lipophilic statins as part of the treatment of ovarian cancer," Visvanathan said in a meeting news release. Still, the results need to be confirmed in clinical trials and other populations before becoming part of standard practice, she said.

Dr. Veena John is head of gynecologic medical oncology at Northwell Health Cancer Institute in Lake Success, N.Y. Reading over the new findings, she said it "supports many other studies that have shown statins as an active agent in treatment of ovarian cancer."

John agreed that while the results of this retrospective study are "exciting," what's really needed is a gold-standard prospective clinical trial, where patients receive either a statin or a placebo and their outcomes are then tracked over time.

"At this time there is not enough evidence to start prescribing statins to prevent or treat ovarian cancer," John said, but she is "looking forward to a randomized prospective study to confirm these findings."

Study results presented at medical meetings are typically considered preliminary until published in a peer-reviewed journal.

More information

For more on ovarian cancer, see the American Cancer Society.